2020
The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials
Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta S. The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clinical Radiology 2020, 76: 155.e25-155.e34. PMID: 33268083, DOI: 10.1016/j.crad.2020.09.024.Peer-Reviewed Original ResearchConceptsInterventional radiologistsClinical trial teamsTrial teamPercutaneous image-guided biopsyLung Cancer EliminationLung cancer trialsEvidence of viabilityImage-guided biopsyLesion scoring systemBiomarker analysisCancer trialsTargeted therapyCancer eliminationScore's abilityInterventional radiologyMultivariate analysisLesionsBiopsySolid massFollowing criteriaModerate agreementMultidisciplinary approachTrialsScoresBiomarkers
2015
Targeted Therapy in Solid Tumors: Lung Cancer
Waqar S, Morgensztern D, Herbst R. Targeted Therapy in Solid Tumors: Lung Cancer. 2015, 224-230. DOI: 10.1002/9781118468678.ch23.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerManagement of NSCLCMetastatic non-small cell lung cancerChoice of regimensUnprecedented response ratesProgression-free survivalEarly-stage diseaseIncurable metastatic diseaseCell lung cancerImproved cure ratesToxic treatment optionsMetastatic diseaseStage diseaseCure rateTreatment optionsTargeted therapyToxicity profileSecondary resistanceResponse rateSolid tumorsPatientsTumor progressionTherapyTumorsMolecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014. Journal Of Thoracic Oncology 2015, 10: s1-s63. PMID: 25535693, PMCID: PMC4346098, DOI: 10.1097/jto.0000000000000405.Peer-Reviewed Original Research
2014
A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer
Vasan N, Boyer JL, Herbst RS. A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer. Clinical Cancer Research 2014, 20: 3921-3930. PMID: 24893629, PMCID: PMC5369356, DOI: 10.1158/1078-0432.ccr-13-1762.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerLung cancerClinical trialsNew clinical trialsEarly clinical trialsPathway-targeted therapiesTargeted therapyMechanism of activityNovel targetCancerDruggable targetsTherapyDisappointing resultsHuman cancersSmall-molecule screenFarnesyltransferase inhibitorsRAS gene productsNew RATrialsPharmaceutical companiesNumerous oncogenesNumerous studiesSynthetic lethality screenPathway
2011
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discovery 2011, 1: 44-53. PMID: 22586319, PMCID: PMC4211116, DOI: 10.1158/2159-8274.cd-10-0010.Peer-Reviewed Original ResearchConceptsLung cancer patientsCancer patientsNon-small cell lung cancer patientsLung Cancer Elimination (BATTLE) trialCell lung cancer patientsDisease control rateCore needle biopsy specimensLung cancer clinical trialsSpecific patient populationsLung cancer therapyNeedle biopsy specimensCancer clinical trialsRelevant molecular biomarkersKRAS patientsNSCLC patientsPatient populationRandomization periodControl rateLaboratory findingsLung cancerBiopsy specimensClinical trialsTargeted therapyBATTLE TrialIndividualized treatment
2010
Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial.
Herbst R, Blumenschein G, Kim E, Lee J, Tsao A, Alden C, Liu S, Stewart D, Wistuba I, Hong W. Sorafenib treatment efficacy and KRAS biomarker status in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial. Journal Of Clinical Oncology 2010, 28: 7609-7609. DOI: 10.1200/jco.2010.28.15_suppl.7609.Peer-Reviewed Original Research
2009
Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium
Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West H, Herbst R, Johnson D, Bunn P, Govindan R. Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium. Journal Of Thoracic Oncology 2009, 4: 930-935. PMID: 19550249, DOI: 10.1097/jto.0b013e3181a9a03b.Peer-Reviewed Original ResearchConceptsLung cancerTargeted therapyGastrointestinal stromal tumorsCancer-related deathChronic myeloid leukemiaCancer SymposiumCytotoxic chemotherapyStromal tumorsMyeloid leukemiaBreast cancerCancerTherapyMolecular targetsCancer therapyTreatmentStriking improvementConsiderable optimismAnnual MeetingCancer genomicsChemotherapyInternational AssociationPatientsLeukemiaTumorsYears
2008
Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study
Tran H, Kim E, Lee J, Herbst R, Liu S, Wistuba I, Yan S, Mao L, Hong W, Heymach J. Correlation between plasma cytokine/angiogenic factors (C/AF) and signaling pathways activation from baseline tumor biopsy specimens in patients with advanced non small cell lung cancer (NSCLC): Preliminary analysis from the Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) Clinical Study. Journal Of Clinical Oncology 2008, 26: 8010-8010. DOI: 10.1200/jco.2008.26.15_suppl.8010.Peer-Reviewed Original ResearchBATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination
Hong W, Herbst R, Mao L, Kim E. BATTLE: Biomarker-Based Approaches of Targeted Therapy for Lung Cancer Elimination. 2008 DOI: 10.21236/ada485729.Peer-Reviewed Original ResearchNonsmall cell lung cancerLung cancerTargeted therapyAdvanced nonsmall cell lung cancerEpidermal growth factor receptor tyrosine kinase inhibitorsGrowth factor receptor tyrosine kinase inhibitorsReceptor tyrosine kinase inhibitorsLung Cancer EliminationTumor response rateCell lung cancerLung cancer patientsCancer-related deathTyrosine kinase inhibitorsCancer patientsCancer eliminationEGFR mutationsTherapeutic approachesResponse rateCancerCancer typesPatientsKinase inhibitorsTherapyInitial successChemotherapy
2007
A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine
Zhou X, Kim E, Herbst R, Liu S, Wistuba I, Mao L, Lewis J, Lippman S, Hong W, Lee J. A clinical trial design applying Bayesian adaptive randomization for targeted therapy development in lung cancer: A step toward personalized medicine. Journal Of Clinical Oncology 2007, 25: 7697-7697. DOI: 10.1200/jco.2007.25.18_suppl.7697.Peer-Reviewed Original ResearchBiomarker profilesEffective agentResponse rateRandomization ratesLung Cancer EliminationTumor biomarker profilesClinical trial designBayesian adaptive randomizationCancer ptsPrior chemotherapyTreatment armsClinical efficacyLung cancerCancer eliminationEffective therapyLung carcinogenesisTargeted therapyDifferent biomarker profilesTrial designTreatment efficacyBiopsy samplesTherapy trialsPatient entryBiomarker expressionTherapy
2006
Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer
Massarelli E, Herbst RS. Use of Novel Second-Line Targeted Therapies in Non–Small Cell Lung Cancer. Seminars In Oncology 2006, 33: 9-16. PMID: 16472704, DOI: 10.1053/j.seminoncol.2005.12.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall response rateEpidermal growth factor receptorCell lung cancerLung cancerResponse rateSecond-line therapeutic approachStandard cytotoxic regimensFirst-line treatmentNew treatment optionsLung cancer casesQuality of lifeNew chemotherapeutic agentsCytotoxic regimensGrowth factor receptorRefractory settingMetastatic diseaseRefractory diseaseLocal therapyNSCLC treatmentTreatment optionsCancer deathTargeted therapyTreatment outcomesCancer cases
2004
Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer
SHIBUYA K, KOMAKI R, WU W, SHINTANI T, ITASAKA S, ISOBE T, RYAN A, HERBST R, OREILLY M. Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s149-s150. DOI: 10.1016/s0360-3016(04)01118-6.Peer-Reviewed Original ResearchTargeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer
Shibuya K, Komaki R, Wu W, Shintani T, Itasaka S, Isobe T, Ryan A, Herbst R, O’Reilly M. Targeted therapy against VEGFR and EGFR signaling with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic mouse model of human non-small cell lung cancer. International Journal Of Radiation Oncology • Biology • Physics 2004, 60: s149-s150. DOI: 10.1016/j.ijrobp.2004.06.061.Peer-Reviewed Original Research
2003
Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens
Blumenschein GR, Herbst RS. Integration of Targeted Therapies in Gemcitabine Chemotherapy Regimens. Clinical Lung Cancer 2003, 4: 217-223. PMID: 14624709, DOI: 10.3816/clc.2003.n.001.Peer-Reviewed Original ResearchLung cancerTargeted therapyCell lung cancerReceptor-targeted therapyLung cancer casesHigh mortality rateSpecific biologic pathwaysAdvanced NSCLCChemotherapy regimensCell cycle inhibitionMost patientsCommon malignancyPoor prognosisCancer casesTherapeutic improvementRadiation therapyEncouraging activityNew agentsMortality rateAngiogenesis inhibitionSingle agentClinical testingSurvival rateTherapyTargeted therapeutics
2002
Targeted therapy in non-small-cell lung cancer.
Herbst RS. Targeted therapy in non-small-cell lung cancer. Oncology 2002, 16: 19-24. PMID: 12375797.Peer-Reviewed Original ResearchMeSH KeywordsAngiogenesis InhibitorsAntibodies, MonoclonalAntineoplastic AgentsCarcinoma, Non-Small-Cell LungClinical Trials as TopicEndothelial Growth FactorsErbB ReceptorsHumansIntercellular Signaling Peptides and ProteinsLung NeoplasmsLymphokinesProtein Kinase CVascular Endothelial Growth Factor AVascular Endothelial Growth FactorsConceptsCell lung cancerLung cancerSuch new agentsNew agentsVascular endothelial growth factor inhibitorsPlatinum-based combination therapyEGFR tyrosine kinase inhibitorsGrowth factor receptor inhibitorsNew biologic therapiesGrowth factor inhibitorsEpithelial growth factor receptor inhibitorTyrosine kinase inhibitorsSpecific biologic pathwaysDevelopment of agentsSignal transduction inhibitorsMaintenance therapyBiologic therapyCytotoxic chemotherapyStages of treatmentFactor inhibitorsCombination therapyTargeted therapyReceptor inhibitorsRadiation therapyClinical investigationTargeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.
Fan D, Yano S, Shinohara H, Solorzano C, Van Arsdall M, Bucana CD, Pathak S, Kruzel E, Herbst RS, Onn A, Roach JS, Onda M, Wang QC, Pastan I, Fidler IJ. Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. Molecular Cancer Therapeutics 2002, 1: 595-600. PMID: 12479219.Peer-Reviewed Original ResearchMeSH KeywordsADP Ribose TransferasesAnimalsBacterial ToxinsDose-Response Relationship, DrugExotoxinsFlow CytometryHumansImmunoglobulin FragmentsImmunotherapyKineticsLung NeoplasmsMesothelinMiceMice, NudeMicroscopy, FluorescenceMutationNeoplasm TransplantationPseudomonasRecombinant ProteinsTumor Cells, CulturedVirulence FactorsConceptsTargeted therapyNude miceHuman non-small cell lung cancer cellsNon-small cell lung cancer cellsNCI-H226 cellsHuman lung cancer cell linesCell lung cancer cellsSquamous cell carcinomaLung cancer cell linesHuman lung cancerExperimental lung metastasisLung cancer cellsPC14PE6 cellsCancer cell linesLung metastasesCell carcinomaCancer patientsLung cancerOvarian cancerNontoxic doseMesothelinDay 7Recombinant immunotoxinCertain cancersCancerTargeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer
Herbst RS. Targeted Therapy Using Novel Agents in the Treatment of Non—Small-Cell Lung Cancer. Clinical Lung Cancer 2002, 3: s30-s38. PMID: 14720353, DOI: 10.3816/clc.2002.s.006.Peer-Reviewed Original ResearchCell lung cancerVascular endothelial growth factorProtein kinase C inhibitorLung cancerKinase C inhibitorSpecific cellular mechanismsCell cycle inhibitionEGFR tyrosine kinaseSignal transductionTyrosine kinaseKey enzymeReceptor-targeted therapyTreatment of NSCLCTumor growth delayC inhibitorEndothelial growth factorCellular mechanismsOSI-774IMC-C225Advanced NSCLCPoor prognosisMajor classesTargeted therapyNovel agentsTherapeutic improvement